Report of Foreign Issuer (6-k)
January 16 2018 - 7:03AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of January 2018
Commission File Number 001-37846
CELLECT BIOTECHNOLOGY LTD.
(Translation of registrant’s name into
English)
23 Hata’as Street
Kfar Saba, Israel 44425
(Address of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F
x
Form
40-F
¨
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):
¨
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):
¨
The first and third sentences of the first
paragraph and “Forward Looking Statements” of the press release attached to this Form 6-K are incorporated by reference
into the registrant’s Registration Statements on Form S-8 (Registration No. 333-214817 and 333-220015) and on Form F-3
(Registration No. 333-219614 and 333-212432).
Attached hereto as Exhibit 99.1 and incorporated
by reference herein is a press release issued by the Registrant titled “Cellect Announces Opening of a Second Clinical Trial
Site and Approval from Safety Board (DSMB) for Dose Escalation.”
Exhibit
1
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
Cellect Biotechnology Ltd.
|
|
|
|
Date: January 16, 2018
|
By:
|
/s/ Eyal Leibovitz
|
|
|
Name: Eyal Leibovitz
|
|
|
Title: Chief Financial Officer
|
Cellect Biotechnology (NASDAQ:APOP)
Historical Stock Chart
From Jul 2024 to Aug 2024
Cellect Biotechnology (NASDAQ:APOP)
Historical Stock Chart
From Aug 2023 to Aug 2024